Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
| Autor: | Stephanie L. Hines, Miroslaw Mazurczak, Steve R. Alberts, Edith A. Perez, David B. Johnson, S. P. Kahanic, Daniel A. Nikcevich, Betty A. Mincey, Heshan Liu, Jeff A. Sloan, Todor Dentchev, Charles L. Loprinzi, Paul L. Schaefer |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Bone density medicine.drug_class Osteoporosis Urology Antineoplastic Agents Breast Neoplasms Zoledronic Acid Article Drug Administration Schedule Bone Density Nitriles medicine Humans Osteoporosis Postmenopausal Aged Femoral neck Aged 80 and over Aromatase inhibitor Bone Density Conservation Agents Diphosphonates business.industry Letrozole Imidazoles Middle Aged Triazoles medicine.disease Surgery Osteopenia Tamoxifen Zoledronic acid medicine.anatomical_structure Oncology Female business medicine.drug |
| Zdroj: | Breast Cancer Research and Treatment. 117:603-609 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-009-0332-2 |
| Popis: | Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized to upfront or delayed zoledronic acid 4 mg every 6 months. Patients in the delayed arm were only given zoledronic acid if they developed a post-baseline BMD T score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink